选择性钙离子通道阻滞剂联合选择性5-羟色胺再摄取抑制剂治疗肠易激综合征的Meta分析

目的 系统评价选择性钙离子通道阻滞剂(SCCBs)联合选择性5-羟色胺再摄取抑制剂(SSRIs)治疗肠易激综合征(IBS)的疗效和安全性.方法 检索PubMed、Embase、Web of Science、Cochrane Library、CBM、CNKI、万方和维普等数据库,获取2020年1月30日之前发表的SCCB...

Efficacy and safety of selective calcium channel blockers plus selective serotonin reuptake inhibitors in the treatment of irritable bowel syndrome:a systematic review and Meta-analysis

Objective To systematically evaluate the efficacy and safety of selective calcium channel blockers(SCCBs)plus selective serotonin reuptake inhibitors(SSRIs)in the treatment of irritable bowel syndrome(IBS).Methods All randomized controlled trials(RCTs)of SCCBs plus SSRIs for IBS,published before Jan.30th,2020,were collected by searching databases such as PubMed,Embase,Web of Science,Cochrane Library,CBM,CNKI,WanFang and VIP.The corresponding outcomes were extracted after literature screening and quality evaluation,and RevMan 5.3 and Stata 14.2 were used for Meta-analysis.Results Thirteen RCTs including 1306 patients were identified.The results of Meta-analysis showed that the total effective rate of the combined treatment group was significantly improved compared with SCCBs alone(RR=1.31,95%CI:1.20-1.43,P<0.00001).After treatment,anxiety scores(SMD=-0.72,95%CI:-1.30--0.14,P=0.02)and depression scores(SMD=-0.97,95%CI:-1.18--0.76,P<0.00001)were statistically lower than SCCBs alone,while there was no significant difference in the incidence of adverse reactions between two groups(RR=0.72,95%CI:0.37-1.38,P=0.32).Conclusion The efficacy of SCCBs plus SSRIs is superior to SCCBs alone in the treatment of IBS without increased adverse reactions.